Abstract:Objective: To conduct a systematic review and meta-analysis of case-control and cohort human studies evaluating metabolite markers identified using high-throughput metabolomics techniques on esophageal cancer (EC), cancer of the gastroesophageal junction (GEJ), and gastric cancer (GC) in blood and tissue. Background: Upper gastrointestinal cancers (UGC), predominantly EC, GEJ, and GC, are malignant tumour types with high morbidity and mortality rates. Numerous studies have focused on metabolomic profiling of UGC in recent years. In this systematic review and meta-analysis, we have provided a collective summary of previous findings on metabolites and metabolomic profiling associated with EC, GEJ and GC. Methods: Following the PRISMA procedure, a systematic search of four databases (Embase, PubMed, MEDLINE, and Web of Science) for molecular epidemiologic studies on the metabolomic profiles of EC, GEJ and GC was conducted and registered at PROSPERO (CRD42023486631). The Newcastle-Ottawa Scale (NOS) was used to benchmark the risk of bias for case-controlled and cohort studies. QUADOMICS, an adaptation of the QUADAS-2 (Quality Assessment of Diagnostic Accuracy) tool, was used to rate diagnostic accuracy studies. Original articles comparing metabolite patterns between patients with and without UGC were included. Two investigators independently completed title and abstract screening, data extraction, and quality evaluation. Meta-analysis was conducted whenever possible. We used a random effects model to investigate the association between metabolite levels and UGC. Results: A total of 66 original studies involving 7267 patients that met the required criteria were included for review. 169 metabolites were differentially distributed in patients with UGC compared to healthy patients among 44 GC, 9 GEJ, and 25 EC studies including metabolites involved in glycolysis, anaerobic respiration, tricarboxylic acid cycle, and lipid metabolism. Phosphatidylcholines, eicosanoids, and adenosine triphosphate were among the most frequently reported lipids and metabolites of cellular respiration, while BCAA, lysine, and asparagine were among the most commonly reported amino acids. Previously identified lipid metabolites included saturated and unsaturated free fatty acids and ketones. However, the key findings across studies have been inconsistent, possibly due to limited sample sizes and the majority being hospital-based case-control analyses lacking an independent replication group. Conclusion: Thus far, metabolomic studies have provided new opportunities for screening, etiological factors, and biomarkers for UGC, supporting the potential of applying metabolomic profiling in early cancer diagnosis. According to the results of our meta-analysis especially BCAA and TMAO as well as certain phosphatidylcholines should be implicated into the diagnostic procedure of patients with UGC. We envision that metabolomics will significantly enhance our understanding of the carcinogenesis and progression process of UGC and may eventually facilitate precise oncological and patient-tailored management of UGC.

A systematic review of metabolomic profiling of gastric cancer and esophageal cancer

Metabolomic profiling of upper GI malignancies in blood and tissue: a systematic review and meta-analysis

Interactions between gastric microbiota and metabolites in gastric cancer

Causal association between metabolites and upper gastrointestinal tumors: A Mendelian randomization study

Microbiota and metabolites alterations in proximal and distal gastric cancer patients

The Combination of Exon Sequencing and Metabolomics to Establish a Molecular Typing System for Gastric Cancer

Metabolomic Phenotype of Gastric Cancer and Precancerous Stages Based on Gas Chromatography Time-of-flight Mass Spectrometry.

Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum.

Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS.

The Distinctive Serum Metabolomes of Gastric, Esophageal and Colorectal Cancers

&Lt;p>differential Metabolic Alterations and Biomarkers Between Gastric Cancer and Colorectal Cancer: A Systematic Review and Meta-Analysis</p>

Urinary metabonomic study on colorectal cancer.

Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with esophageal cancer

Application of metabolomics in clinical and laboratory gastrointestinal oncology

Metabolic Perturbation and Potential Markers in Patients with Esophageal Cancer

Metabolomics of Esophageal Squamous Cell Carcinoma Tissues: Potential Biomarkers for Diagnosis and Promising Targets for Therapy

Serum Metabolic Profiling of Human Gastric Cancer Based on Gas Chromatography/mass Spectrometry

Metabolomic Investigation of Gastric Cancer Tissue Using Gas Chromatography/mass Spectrometry

Tissue Metabolomic Fingerprinting Reveals Metabolic Disorders Associated with Human Gastric Cancer Morbidity.

Serum Metabolomic Profiling of Human Gastric Cancer and Its Relationship with the Prognosis